Myovant Sciences Ltd.
MYOVDelisted Mar 10, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001679082
Myovant Sciences Ltd. was delisted on Mar 10, 2023; its insiders filed their last Form 4 on Mar 10, 2023; 118 institutions reported holding it in 13F filings for Q4 2022, worth $1.12B in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Myovant Sciences Ltd. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Myovant Sciences Ltd., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Sumitomo Pharma Co., Ltd. | 10% Owner | 45,798,176Indirect | Mar 10, 2023 | 0 |
| Sumitovant Biopharma Ltd. | 10% Owner | 45,798,176Indirect | Mar 10, 2023 | 0 |
| Sumitomo Chemical Co., Ltd. | 10% Owner | 45,798,176Indirect | Mar 10, 2023 | 0 |
| Potter Myrtle S | Director | 0 | Mar 10, 2023 | 0 |
| Guinan Mark | Director | 0 | Mar 10, 2023 | 0 |
| Marek David C | Principal Executive Officer | 0 | Mar 10, 2023 | 0 |
| Gulfo Adele M. | Director | 0 | Mar 10, 2023 | 0 |
| Curran Terrie | Director | 0 | Mar 10, 2023 | 0 |
| Lang Matthew | General Counsel & Corp. Secy. | 0 | Mar 10, 2023 | 0 |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | 0 | Mar 10, 2023 | 0 |
| Merendino Lauren | Chief Commercial Officer | 0 | Mar 10, 2023 | 0 |
| Mehra Uneek | Principal Financial Officer | 0 | Mar 10, 2023 | 0 |
| Valente Nancy | Director | 0 | Mar 10, 2023 | 0 |
| Karbe Frank | Principal Fin'l & Accounting | 212,296 | Jul 9, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 20, 2022 (view filing) | Oct 18 | 2 days | Marek David CPrincipal Executive Officer | SSale | −11.2K | $25.20 | −$281.1K | −2.6%425.6K after | |
| Oct 20, 2022 (view filing) | Oct 18 | 2 days | Merendino LaurenChief Commercial Officer | SSale | −1.70K | $25.20 | −$42.9K | −1.0%171.5K after | |
| Dec 20, 2022 (view filing) | Dec 16 | 4 days | Mehra UneekPrincipal Financial Officer | SSale | −2.24K | $26.75 | −$59.9K | −1.1%202.7K after | |
| Jan 5, 2023 (view filing) | Jan 4 | 1 day | Lang MatthewGeneral Counsel & Corp. Secy. | SSale | −2.78K | $26.90 | −$74.8K | −0.8%355.6K after | |
| Jan 5, 2023 (view filing) | Jan 4 | 1 day | Arjona Ferreira Juan CamiloChief Medical Officer | SSale | −2.25K | $26.90 | −$60.6K | −0.9%247.8K after | |
| Jan 20, 2023 (view filing) | Jan 18 | 2 days | Arjona Ferreira Juan CamiloChief Medical Officer | SSale | −1.11K | $26.89 | −$29.8K | −0.4%246.7K after | |
| Jan 20, 2023 (view filing) | Jan 18 | 2 days | Marek David CPrincipal Executive Officer | SSale | −8.04K | $26.89 | −$216.1K | −1.9%417.6K after | |
| Jan 20, 2023 (view filing) | Jan 18 | 2 days | Merendino LaurenChief Commercial Officer | SSale | −2.01K | $26.89 | −$54.0K | −1.2%169.5K after | |
| Jan 20, 2023 (view filing) | Jan 18 | 2 days | Lang MatthewGeneral Counsel & Corp. Secy. | SSale | −1.27K | $26.89 | −$34.2K | −0.4%354.3K after | |
| Mar 10, 2023 (view filing)9:17 AM ET | Mar 10 | Same day | Sumitomo Pharma Co., Ltd. and 2 others10% Owner | PPurchase | +51.6M | $27.00 | +$1.39B | New position45.8M after |